Company intelligence / Profile preview

Phosphate Therapeutics

Gateshead, Tyne and Wear, United Kingdomprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Phosphate Therapeutics developed PT20, a mineral-derived oral phosphate binder for the treatment of hyperphosphatemia in patients with dialysis-dependent chronic kidney disease. A Phase 2 clinical trial evaluating efficacy and safety has been completed. No additional programs or later-stage results are publicly reported.

Therapeutic areas: Nephrology
Modalities: Small moleculeMineral-derived drug
Industry: Biotech

Drug pipeline

1 asset

PT20

Phase 2

Indications: Hyperphosphatemia

Beyond the preview

Go deeper on Phosphate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphate Therapeutics.

Explore the full profile